BM Heparin Sodium Injection 25000 units

Adult administration

Generally administered by intravenous injection or added to blood during extracorporeal circulation. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Administer 1,000 to 5,000 IU of heparin sodium before starting dialysis, and after starting dialysis, continuously administer an additional 500 to 1,500 IU per hour or intermittently add 500 to 1,500 IU every hour. (2) Local heparinization

This drug is very potent, so it should only be used under strict medical supervision. Patients with diseases at high risk for bleeding should use caution, as bleeding can occur in almost any part of the body for patients who have received this drug. In rare cases, fatal bleeding may occur, and severe bleeding such as adrenal hemorrhage, ovarian hemorrhage, and retroperitoneal hemorrhage have also been reported. Additionally, benzyl alcohol present in this drug can cause severe respiratory issues in premature infants, so it should not be used in newborns and premature babies. Patients allergic to this drug or its components, patients with inappropriate results on blood coagulation tests, and patients with bleeding or at high risk of bleeding should not be administered this drug. Patients with severe liver or kidney diseases, those who have recently undergone central nerve system or eye surgery, and those who have received spinal or epidural anesthesia should also avoid use. While administering this drug, blood coagulation status should be regularly monitored, and if any signs of bleeding occur, use of the drug should be stopped immediately. Platelet counts should also be continuously monitored, and if a rapid decrease is found, administration should be discontinued. This drug can interact with other medications, so caution is needed when used in combination with acetylsalicylic acid or non-steroidal anti-inflammatory drugs, anticoagulants, and thrombolytics, as the risk of bleeding may increase. Pregnant or breastfeeding women should be particularly cautious due to the risk of bleeding in the uterus and placenta and during delivery, although it does not pass into breast milk, caution is still needed because of the benzyl alcohol component. Elderly patients or children should use this drug carefully as they may have an elevated risk of bleeding or the safety has not been established. In case of overdose, bleeding complications may occur, and if necessary, the antidote protamine sulfate should be used to neutralize it; the antidote must also be considered for potential side effects. During treatment, intramuscular injections should be avoided, and it is safe not to mix antihistamines and injections.

Serious side effects

Urticaria, angioedema, respiratory distress, shock, severe bleeding, adrenal hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage, thrombocytopenia, heparin-induced thrombocytopenia, thrombosis, cyanosis, bronchial asthma, vascular spasm reactions, reduced platelet count (thrombocytopenia), thrombosis, severe allergic reactions

Mild side effects

Itching, chills, fever, rhinitis, tearing, conjunctivitis, tachycardia, pressure sensation, nausea, vomiting, hypotension, bronchospasm, hair loss, vitiligo, hemorrhagic necrosis, hypoaldosteronism, osteoporosis, rebound effects, dyslipidemia, suppression of kidney function, local pain hematomas from subcutaneous or intramuscular injections, priapism, diabetes, hyperkalemia, hyperaldosteronism, metabolic acidosis, elevated lipase, erythema, mild pain, ulcers

This drug should be stored in a sealed container that protects it from light, at room temperature between 1 and 30 degrees Celsius. By storing it this way, the effectiveness of the drug can be maintained for a longer period.

Appearance

A transparent liquid that is colorless or pale yellow, contained in a brown vial

Package unit

5mL/vial X 10 vials